acute myeloid leukemia (AML)

Dr. Cutler received his MD from McGill University, Montreal, Canada. He subsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff.

Dr. M. Sitki Copur is a nationally known medical oncologist. He is an adjunct faculty professor at the University of Nebraska Medical Center Department of Internal Medicine Division of Hematology/Oncology. He graduated from medical school at Hacettepe University in Ankara, Turkey.

Dr. Brunner's clinical area of focus and research projects are focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. The therapies available for patients with MDS have not changed in the last decade, and there is critical need to develop new agents and identify the patients most likely to benefit from a given

Ehab Atallah, MD, is a Professor of Medicine and Section Head of hematological malignancies in the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and

Dr. Erba entered medical school for the sole purpose of learning more about human diseases, so that he could focus his laboratory efforts on improving the human condition. However, he was surprised to find himself drawn to clinical care. He cares for people afflicted by acute leukemia,

Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She has completed formal training in